marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 10-29-2024
Sage Therapeutics Balance Sheet 2011-2024 | SAGE
Annual Balance Sheet Sage Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-151 M | -276 M | - | -89.6 M | -191 M | -306 M | -169 M | -187 M | -128 M | -8.07 M | -2.8 M | - | |
Long Term Debt |
- | 4.49 M | 11 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
5.16 M | 7.64 M | 7.47 M | 8.66 M | 10.2 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 27.4 M | 3.7 M | 2.51 M | 845 K | 14 K | 23 K | 37.8 M | 15 M | - |
Total Current Liabilities |
82.7 M | 99.3 M | 85.2 M | 67.2 M | 112 M | 86 M | 52 M | 35.2 M | 15.3 M | 7.76 M | - | - | - |
Total Liabilities |
82.7 M | 104 M | 96.3 M | 86.9 M | 139 M | 89.7 M | 54.5 M | 36 M | 15.3 M | 7.78 M | 40.1 M | 16.4 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.57 B | -2.03 B | -1.5 B | -1.04 B | -1.64 B | -963 M | -590 M | -320 M | -161 M | -66.8 M | -31.7 M | -13.4 M | - |
Total Assets |
882 M | 1.36 B | 1.83 B | 2.16 B | 1.08 B | 953 M | 530 M | 405 M | 189 M | 130 M | 8.53 M | 3 M | - |
Cash and Cash Equivalents |
71 M | 163 M | 294 M | 1.66 B | 127 M | 191 M | 306 M | 169 M | 187 M | 128 M | 8.07 M | 2.8 M | - |
Book Value |
800 M | 1.25 B | 1.73 B | 2.07 B | 945 M | 863 M | 475 M | 369 M | 174 M | 122 M | -31.5 M | -13.4 M | - |
Total Shareholders Equity |
800 M | 1.25 B | 1.73 B | 2.07 B | 945 M | 863 M | 475 M | 369 M | 174 M | 122 M | -31.5 M | -13.4 M | - |
All numbers in USD currency
Quarterly Balance Sheet Sage Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
10.2 M | - | - | - | - | 1 M | 2.76 M | 4.49 M | 6.16 M | - | 9.4 M | 11 M | 12.5 M | 14 M | 15.4 M | 19.4 M | 19.4 M | 19.4 M | 19.4 M | 26.8 M | 26.8 M | 26.8 M | 26.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
70.6 M | 69 M | 61.8 M | 82.7 M | 133 M | 97.9 M | 87.6 M | 104 M | 106 M | - | 87.2 M | 96.3 M | 91.5 M | 86 M | 77.4 M | 86.9 M | 86.9 M | 86.9 M | 86.9 M | 139 M | 139 M | 139 M | 139 M | 89.7 M | 89.7 M | 89.7 M | 89.7 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 36 M | 36 M | 36 M | 36 M | 15.3 M | 15.3 M | 15.3 M | 15.3 M | 7.78 M | 7.78 M | 7.78 M | 7.78 M | 2.36 M | 2.36 M | 2.36 M | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-2.87 B | -2.78 B | -2.68 B | -2.57 B | -2.54 B | -2.34 B | -2.17 B | -2.03 B | -1.88 B | - | -1.62 B | -1.5 B | -1.37 B | -1.24 B | -1.13 B | -1.04 B | -1.04 B | -1.04 B | -1.04 B | -1.64 B | -1.64 B | -1.64 B | -1.64 B | -963 M | -963 M | -963 M | -963 M | -590 M | -590 M | -590 M | -590 M | -320 M | -320 M | -320 M | -320 M | -161 M | -161 M | -161 M | -161 M | -66.8 M | -66.8 M | -66.8 M | -66.8 M | -31.7 M | -31.7 M | -31.7 M | - | - | - | - | - | - | - | - | - |
Total Assets |
622 M | 697 M | 768 M | 882 M | 950 M | 1.08 B | 1.22 B | 1.36 B | 1.49 B | - | 1.71 B | 1.83 B | 1.93 B | 2.02 B | 2.08 B | 2.16 B | 2.16 B | 2.16 B | 2.16 B | 1.08 B | 1.08 B | 1.08 B | 1.08 B | 953 M | 953 M | 953 M | 953 M | 530 M | 530 M | 530 M | 530 M | 405 M | 405 M | 405 M | 405 M | 189 M | 189 M | 189 M | 189 M | 130 M | 130 M | 130 M | 130 M | 8.53 M | 8.53 M | 8.53 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
99.6 M | 99.9 M | 173 M | 71 M | 149 M | 121 M | 207 M | 163 M | 200 M | - | 179 M | 294 M | 422 M | 514 M | 899 M | 1.66 B | 1.66 B | 1.66 B | 1.66 B | 127 M | 127 M | 127 M | 127 M | 191 M | 191 M | 191 M | 191 M | 306 M | 306 M | 306 M | 306 M | 169 M | 169 M | 169 M | 169 M | 187 M | 187 M | 187 M | 187 M | 128 M | 128 M | 128 M | 128 M | 8.07 M | 8.07 M | 8.07 M | - | 2.8 M | - | - | - | 2.84 M | - | - | - |
Book Value |
552 M | 628 M | 706 M | 800 M | 817 M | 984 M | 1.13 B | 1.25 B | 1.38 B | - | 1.62 B | 1.73 B | 1.84 B | 1.93 B | 2 B | 2.07 B | 2.07 B | 2.07 B | 2.07 B | 945 M | 945 M | 945 M | 945 M | 863 M | 863 M | 863 M | 863 M | 475 M | 475 M | 475 M | 475 M | 369 M | 369 M | 369 M | 369 M | 174 M | 174 M | 174 M | 174 M | 122 M | 122 M | 122 M | 122 M | 6.17 M | 6.17 M | 6.17 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
552 M | 628 M | 706 M | 800 M | 817 M | 984 M | 1.13 B | 1.25 B | 1.38 B | 1.5 B | 1.62 B | 1.73 B | 1.84 B | 1.93 B | 2 B | 2.07 B | 2.07 B | 2.07 B | 2.07 B | 945 M | 945 M | 945 M | 945 M | 863 M | 863 M | 863 M | 863 M | 475 M | 475 M | 475 M | 475 M | 369 M | 369 M | 369 M | 369 M | 174 M | 174 M | 174 M | 174 M | 122 M | 122 M | 122 M | 122 M | -31.5 M | -31.5 M | -31.5 M | - | -13.4 M | - | - | - | -3.76 M | - | - | - |
All numbers in USD currency